Rezolute, Inc. (RZLT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Nevan Charles Elam J.D.
|
Founder, CEO & Acting Chairman of the Board | 1.13M | -- | 1967 |
|
Mr. Daron G. Evans M.B.A., M.S.
|
Chief Financial & Business Officer | 738.05k | -- | 1974 |
|
Dr. Brian Kenneth Roberts M.D.
|
Chief Medical Officer | 789.22k | -- | 1975 |
|
Dr. Sunil Karnawat M.B.A., Ph.D.
|
Chief Commercial Officer | 678.8k | -- | 1967 |
|
Mr. Michael R. Deperro
|
Senior VP & Head of Operations | -- | -- | -- |
|
Dr. Davelyn Eaves Hood M.B.A., M.D.
|
Director and Head of Scientific & Patient Affairs | -- | -- | -- |
|
Ms. Melissa Quinn
|
Senior Director of People and Culture | -- | -- | -- |
|
Ms. Robyn Sweinhart
|
VP & Head of Quality | -- | -- | -- |
|
Ms. Erin O'Boyle
|
Senior VP & Head of Clinical Operations | -- | -- | -- |
|
Ms. Susan Stewart J.D., L.L.M.
|
Chief Regulatory Officer | -- | -- | 1961 |
Rezolute, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 63
Description
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
November 5, 2026 at 9:00 PM UTC
Rezolute, Inc. Earnings Date
